MCID: RSP002
MIFTS: 51

Respiratory Syncytial Virus Infectious Disease

Categories: Infectious diseases

Aliases & Classifications for Respiratory Syncytial Virus Infectious Disease

MalaCards integrated aliases for Respiratory Syncytial Virus Infectious Disease:

Name: Respiratory Syncytial Virus Infectious Disease 12
Respiratory Syncytial Virus Infections 43 71
Respiratory Syncytial Virus Infection 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1273
MeSH 43 D018357
NCIt 49 C3354
SNOMED-CT 67 55735004
UMLS 71 C0035235

Summaries for Respiratory Syncytial Virus Infectious Disease

Disease Ontology : 12 A viral infectious disease that results in infection located in upper respiratory tract or located in lower respiratory tract, has material basis in Human respiratory syncytial virus, which is transmitted by droplet spread of nasal secretions from an infected person while coughing or sneezing, or transmitted by contaminated fomites. The infection has symptom runny nose, has symptom fever, has symptom cough, has symptom wheezing, and has symptom respiratory distress.

MalaCards based summary : Respiratory Syncytial Virus Infectious Disease, also known as respiratory syncytial virus infections, is related to cytokine deficiency and bronchiolitis, and has symptoms including fever, cough and respiratory distress. An important gene associated with Respiratory Syncytial Virus Infectious Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Immunoglobulins, Intravenous and Palivizumab have been mentioned in the context of this disorder. Affiliated tissues include upper respiratory tract, lower respiratory tract and testes.

Related Diseases for Respiratory Syncytial Virus Infectious Disease

Diseases related to Respiratory Syncytial Virus Infectious Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 286)
# Related Disease Score Top Affiliating Genes
1 cytokine deficiency 31.5 IL5 IL13
2 bronchiolitis 31.4 IL5 IL13 CCL5 CCL3
3 hypereosinophilic syndrome 31.1 IL5 IL13 CCL5
4 otitis media 31.0 IL5 IL13 CCL5
5 ige responsiveness, atopic 31.0 IL5 IL13
6 bronchitis 31.0 IL5 IL13 CCL5
7 eosinophilic pneumonia 30.8 IL5 IL13 CCL5
8 rhinitis 30.7 IL5 IL13 CCL5
9 viral pneumonia 30.5 IFNB1 CCL5
10 respiratory failure 30.5 SFTPB IL5 IL13 CCL5
11 lung disease 30.4 SFTPB IL5 IL13 CCL5 CCL3
12 pulmonary eosinophilia 30.3 IL5 IL13 CCL5 CCL3
13 allergic asthma 30.3 IL5 IL13 CCL5 CCL3
14 pollen allergy 30.3 IL5 IL13
15 bacterial pneumonia 30.3 SFTPB NEU1 CCL3
16 common cold 30.2 IL5 IL13 CCL5
17 respiratory allergy 30.2 IL5 IL13 CCL5
18 allergic rhinitis 30.2 IL5 IL13 CCL5
19 dermatitis, atopic 30.1 IL5 IL13 CCL5
20 allergic conjunctivitis 30.0 IL5 IL13
21 aspergillosis 30.0 IL5 CCL5 CCL3
22 proteasome-associated autoinflammatory syndrome 1 30.0 IL5 IL13 CCL5 CCL3
23 bronchial disease 30.0 IL5 IL13 CCL5
24 influenza 29.9 NEU1 IFNB1 CCL5
25 japanese encephalitis 29.8 IFNB1 CCL5
26 severe combined immunodeficiency 29.7 IL5 IL13 IFNB1
27 severe acute respiratory syndrome 29.7 IFNB1 CCL5 CCL3
28 encephalitis 29.7 IFNB1 CCL5 CCL3
29 interstitial lung disease 29.7 SFTPB IL5 IL13 CCL5
30 celiac disease 1 29.6 IRF1 IL5 IL13
31 allergic hypersensitivity disease 29.6 IL5 IL13 CCL5 CCL3
32 immune deficiency disease 29.3 IL13 IFNB1 CCL5 CCL3
33 pulmonary disease, chronic obstructive 29.3 SFTPB IL5 IL13 CCL5 CCL3
34 diarrhea 29.3 IL5 IL13 IFNB1
35 newcastle disease 29.1 NEU1 IRF1 IFNB1
36 pulmonary fibrosis, idiopathic 29.0 SFTPB IL5 IL13 CCL5 CCL3
37 asthma 28.5 IRF1 IL5 IL13 IFNB1 CCL5 CCL3
38 viral infectious disease 28.3 NEU1 IRF1 IL13 IFNB1 CCL5 CCL3
39 pneumonia 28.2 SFTPB NEU1 IL5 IL13 IFNB1 CCL5
40 systemic lupus erythematosus 27.9 IRF1 IL5 IL13 IFNB1 CCL5 CCL3
41 bronchopulmonary dysplasia 10.9
42 hypotrichosis and recurrent skin vesicles 10.9
43 cystic fibrosis 10.6
44 vaccinia 10.6
45 bacterial infectious disease 10.5
46 haemophilus influenzae 10.5
47 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.5
48 lymphopenia 10.5
49 down syndrome 10.5
50 bronchiolitis obliterans 10.5

Graphical network of the top 20 diseases related to Respiratory Syncytial Virus Infectious Disease:



Diseases related to Respiratory Syncytial Virus Infectious Disease

Symptoms & Phenotypes for Respiratory Syncytial Virus Infectious Disease

Symptoms:

12
  • fever
  • cough
  • respiratory distress
  • wheezing
  • runny nose

UMLS symptoms related to Respiratory Syncytial Virus Infectious Disease:


fever, pruritus, snoring, coughing

Drugs & Therapeutics for Respiratory Syncytial Virus Infectious Disease

Drugs for Respiratory Syncytial Virus Infectious Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins, Intravenous Phase 4
2
Palivizumab Approved, Investigational Phase 2, Phase 3 188039-54-5
3
Ribavirin Approved Phase 3 36791-04-5 37542
4 Calamus Phase 3
5 Antibodies, Monoclonal Phase 2, Phase 3
6 Antiviral Agents Phase 3
7 Anti-Infective Agents Phase 3
8 Pharmaceutical Solutions Phase 3
9 Antimetabolites Phase 3
10
Coal tar Approved Phase 2 8007-45-2
11
tannic acid Approved Phase 2 1401-55-4
12
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
13
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
14
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
15 PC786 Phase 2
16
Histidine Investigational, Nutraceutical Phase 2 71-00-1 6274
17
Midazolam Approved, Illicit Phase 1 59467-70-8 4192
18
Clotrimazole Approved, Vet_approved Phase 1 23593-75-1 2812
19
Itraconazole Approved, Investigational Phase 1 84625-61-6 55283
20
Verapamil Approved Phase 1 52-53-9 2520
21
Rifampicin Approved Phase 1 13292-46-1 5381226 5458213
22
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
23
Prednisone Approved, Vet_approved Phase 1 53-03-2 5865
24
Quinidine Approved, Investigational Phase 1 56-54-2 441074
25
BCG vaccine Investigational Phase 1
26 Antitubercular Agents Phase 1
27 Cytochrome P-450 Enzyme Inhibitors Phase 1
28 Hormone Antagonists Phase 1
29 Anesthetics Phase 1
30 Hormones Phase 1
31 Hypnotics and Sedatives Phase 1
32 Anti-Anxiety Agents Phase 1
33 Psychotropic Drugs Phase 1
34 Anesthetics, General Phase 1
35 Vasodilator Agents Phase 1
36 Anti-Arrhythmia Agents Phase 1
37 GABA Modulators Phase 1
38
Hydroxyitraconazole Phase 1
39 Anti-Bacterial Agents Phase 1
40 Antifungal Agents Phase 1
41 Anesthetics, Intravenous Phase 1
42 Neurotransmitter Agents Phase 1
43 Calcium, Dietary Phase 1
44 Antibiotics, Antitubercular Phase 1
45 polysaccharide-K Phase 1
46 calcium channel blockers Phase 1
47 Cytochrome P-450 CYP3A Inhibitors Phase 1
48 Antineoplastic Agents, Hormonal Phase 1
49 glucocorticoids Phase 1
50 Immunosuppressive Agents Phase 1

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 Prevention of RSV Infections in Bone Marrow Transplant Recipients Completed NCT00001903 Phase 4 RSV Polyclonal Immunoglobulin
2 Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Completed NCT01466062 Phase 3 Palivizumab
3 A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation Completed NCT01006629 Phase 2, Phase 3
4 A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children Completed NCT00129766 Phase 3
5 Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study Completed NCT03171142 Phase 3 Heliox;Air
6 A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants Completed NCT02624947 Phase 3
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants Completed NCT02325791 Phase 3 Suptavumab 30 mg/kg;Placebo Matched to Suptavumab;Suptavumab 30 mg/kg- 1 Dose;Suptavumab 30 mg/kg - 2 Doses
8 A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY) Recruiting NCT03959488 Phase 2, Phase 3 MEDI8897;Palivizumab
9 A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) Recruiting NCT03979313 Phase 3 MEDI8897;Placebo
10 A Randomized, Double-blind, Placebo-controlled, 2-part Study of Orally Administered AK0529 to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Multiple Doses in Hospitalized Infants With Respiratory Syncytial Virus Infection Not yet recruiting NCT04231968 Phase 3 AK0529;Matching placebo of AK0529
11 A Randomized Phase III Study to Evaluate the Safety and Efficacy of Ribavirin Inhaled Solution in Preventing Progression of Upper Respiratory Tract Respiratory Syncytial Virus Infection to RSV Pneumonia in Blood and Bone Marrow Transplant (BMT) Recipient Terminated NCT00031473 Phase 3 Virazole (Ribavirin) Inhalation Solution
12 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model Completed NCT02094365 Phase 2 ALS-008176;vehicle
13 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of RV521 Against Respiratory Syncytial Virus Infection In The Virus Challenge Model Completed NCT03258502 Phase 2 RV521;Placebo
14 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Completed NCT02254421 Phase 2 Presatovir;Placebo
15 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model. Completed NCT03691623 Phase 2 EDP-938 Dose 1;EDP-938 Dose 2;Placebo;EDP-938 Dose 3;EDP-938 Dose 4;Placebo
16 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Completed NCT02135614 Phase 2 Presatovir;Presatovir placebo
17 A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead-in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care. Completed NCT02309320 Phase 1, Phase 2
18 An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults Completed NCT03334695 Phase 2 Placebo
19 A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection Completed NCT03332459 Phase 2 Lumicitabine;Placebo
20 A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects Completed NCT02387606 Phase 2 Placebo;JNJ-53718678
21 A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection Completed NCT02654171 Phase 2 AK0529;Placebo
22 Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain) Completed NCT01756482 Phase 2 GS-5806;Placebo
23 A Phase II Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Particle Vaccine With Aluminum, in Healthy Women of Child-Bearing Age Completed NCT01960686 Phase 2
24 A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness Completed NCT02673476 Phase 2 ALS-008176;Placebo
25 A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus Completed NCT00496821 Phase 2 ALN-RSV01
26 A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Completed NCT01065935 Phase 2 ALN-RSV01;Normal Saline
27 An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women Completed NCT02753413 Phase 2
28 A Multi-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) Completed NCT00658086 Phase 2 ALN-RSV01;normal saline
29 A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model Completed NCT03382431 Phase 1, Phase 2 PC786;Placebo/vehicle
30 A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum, in Healthy Third-trimester Pregnant Women and to Assess the Impact of Maternal Immunization on Infant Safety Through One Year of Life Completed NCT02247726 Phase 2 Saline Placebo (0.5mL injection);RSV F vaccine (0.5mL injection)
31 An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women Completed NCT02360475 Phase 2
32 A Phase 1/2, Open-Label, Repeat-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children at Risk for Serious RSV Disease Completed NCT00192478 Phase 1, Phase 2
33 A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine Completed NCT02873286 Phase 2
34 A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model Completed NCT02718937 Phase 2 BTA-C585 oral capsule;Matching placebo capsules
35 A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Safety and Efficacy of A-60444 in Adults With RSV Infection Following Stem Cell Transplantation Completed NCT00232635 Phase 2 A-60444
36 A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants Completed NCT02878330 Phase 2 MEDI8897;Placebo
37 A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season Completed NCT00316264 Phase 2
38 A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus Completed NCT03379675 Phase 2 JNJ-53718678 500 mg;JNJ-53718678 80 mg;Placebo
39 An Observer-blind Study to Rank Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A) Administered to Healthy Women Completed NCT02956837 Phase 2 Placebo (Formulation buffer S9b)
40 An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant Completed NCT01502072 Phase 2 Ribavirin;Ribavirin
41 A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Orally Administered AK0529 in Adults With Respiratory Syncytial Virus Infection Recruiting NCT03699202 Phase 2 AK0529;Placebo
42 Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, and Efficacy of RV521 in the Treatment of Adult Subjects Who Have Undergone Hematopoietic Cell Transplantation (HCT) With a Documented Upper Respiratory Tract Infection (URTI) With Respiratory Syncytial Virus (RSV) Recruiting NCT04267822 Phase 2 RV521 oral tablet;Placebo oral tablet
43 A Phase II Study of 2 Dose Levels of an Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, to Healthy Non-pregnant Women Active, not recruiting NCT04138056 Phase 2 Placebo
44 A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers Active, not recruiting NCT04126213 Phase 2 Placebo
45 A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants Active, not recruiting NCT02927873 Phase 2 Placebo LD;Placebo MD;Placebo HD
46 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Suspended NCT04056611 Phase 2 JNJ-53718678;Placebo
47 A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children >=28 Days and <=3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection Suspended NCT03656510 Phase 2 JNJ-53718678;Placebo
48 A Double Blind, Placebo-controlled Study to Assess the Anti-viral Effect, Safety and Tolerability of Inhaled PC786 for the Treatment of Acute Respiratory Syncytial Virus (RSV) Infection in Adult Hematopoietic Stem Cell Transplant Recipients Terminated NCT03715023 Phase 2 PC786;Placebo;SOC
49 An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Pregnant Women and Infants Born to Vaccinated Mothers Withdrawn NCT03191383 Phase 2 Placebo (Formulation buffer S9b)
50 A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age Unknown status NCT03213405 Phase 1

Search NIH Clinical Center for Respiratory Syncytial Virus Infectious Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Immunoglobulins, Intravenous
palivizumab
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC]
Ribavirin

Cochrane evidence based reviews: respiratory syncytial virus infections

Genetic Tests for Respiratory Syncytial Virus Infectious Disease

Anatomical Context for Respiratory Syncytial Virus Infectious Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Respiratory Syncytial Virus Infectious Disease:

19
Upper Respiratory Tract, Lower Respiratory Tract

MalaCards organs/tissues related to Respiratory Syncytial Virus Infectious Disease:

40
Testes, Lung, Bone Marrow, Bone, Neutrophil, Heart, T Cells

Publications for Respiratory Syncytial Virus Infectious Disease

Articles related to Respiratory Syncytial Virus Infectious Disease:

(show top 50) (show all 429)
# Title Authors PMID Year
1
Antiviral drugs: current state of the art. 54 61
11418355 2001
2
Advanced Live Attenuated Vaccines for the Prevention of Respiratory Syncytial Virus Infections in Young Children. 61
31549154 2020
3
Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients. 61
32449200 2020
4
A three-dimensional A549 cell culture model to study respiratory syncytial virus infections. 61
32360024 2020
5
Clinical impact and direct costs of nosocomial respiratory syncytial virus infections in the neonatal intensive care unit. 61
32305431 2020
6
Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections. 61
32227102 2020
7
Correction to: Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. 61
31758310 2020
8
Ten years of severe respiratory syncytial virus infections in a tertiary paediatric intensive care unit. 61
31095832 2020
9
Epidemiology, Risk Factors, and Outcomes of Respiratory Syncytial Virus Infections in Newborns in Bamako, Mali. 61
30810160 2020
10
Comparison of health care resource utilization among preterm and term infants hospitalized with Human Respiratory Syncytial Virus infections: A systematic review and meta-analysis of retrospective cohort studies. 61
32084214 2020
11
Respiratory syncytial virus infections in children 0-24 months of age in the community. 61
31521741 2020
12
Assessment and Validation of Syndromic Case Definitions for Respiratory Syncytial Virus Infections in Young Infants: A Latent Class Analysis. 61
31568250 2019
13
Respiratory syncytial virus suppression of the antiviral immune response: Implications for evaluation of candidate vaccines. 61
31607601 2019
14
Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. 61
31718741 2019
15
Respiratory Outcome of the Former Premature Infants. 61
32025257 2019
16
Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor. 61
31517055 2019
17
Respiratory Tract Infections and Voice Quality in 4-Year-old Children in the STEPS Study. 61
29506899 2019
18
Delayed Diagnosis of Respiratory Syncytial Virus Infections in Hospitalized Adults: Individual Patient Data, Record Review Analysis and Physician Survey in the United States. 61
31070757 2019
19
Acute Encephalitis and Myocarditis Associated with Respiratory Syncytial Virus Infections. 61
31380518 2019
20
What is the role of rapid molecular testing for seniors and other at-risk adults with respiratory syncytial virus infections? 61
31158780 2019
21
Genomic analysis of respiratory syncytial virus infections in households and utility in inferring who infects the infant. 61
31296922 2019
22
Comparison of Clinical Characteristics of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Hospitalized Young Children. 61
30814460 2019
23
Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies. 61
31221784 2019
24
Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients. 61
30202920 2019
25
Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease. 61
31143074 2019
26
Respiratory viruses in adults hospitalised with Community-Acquired Pneumonia during the non-winter months in Melbourne: Routine diagnostic practice may miss large numbers of influenza and respiratory syncytial virus infections. 61
30982246 2019
27
Seasonal variation in childhood mortality. 61
30880511 2019
28
Notes from the Field: Respiratory Syncytial Virus Infections in a Neonatal Intensive Care Unit - Louisiana, December 2017. 61
30629570 2019
29
Burden of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Asthmatic Children. 61
29742646 2018
30
An overview of respiratory syncytial virus infections in Saudi Arabia. 61
32012121 2018
31
Respiratory syncytial virus infections in India: Epidemiology and need for vaccine. 61
30880691 2018
32
Respiratory syncytial virüs infections in neonates and infants. 61
30116126 2018
33
Immunization during pregnancy. 61
29715051 2018
34
Case study-based time-course analysis of symptoms of respiratory syncytial virus infections followed by acute sinusitis in otherwise-healthy adults. 61
29997985 2018
35
Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. 61
29360277 2018
36
Dose-dependent relationships between weight status and clinical outcomes among infants hospitalized with respiratory syncytial virus infections. 61
29359458 2018
37
Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections. 61
29463335 2018
38
Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan. 61
29746578 2018
39
Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. 61
29168012 2018
40
A Two-Dimensional Human Minilung System (Model) for Respiratory Syncytial Virus Infections. 61
29232863 2017
41
Elucidation of Bacterial Pneumonia-Causing Pathogens in Patients with Respiratory Viral Infection. 61
28905531 2017
42
Replication defective viral genomes exploit a cellular pro-survival mechanism to establish paramyxovirus persistence. 61
28986577 2017
43
Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates. 61
28926860 2017
44
The Burden of Human Metapneumovirus and Respiratory Syncytial Virus Infections in Hospitalized Norwegian Children. 61
28838133 2017
45
Maternal immunisation: collaborating with mother nature. 61
28433705 2017
46
Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections. 61
28187116 2017
47
In Reply: Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections. 61
28187117 2017
48
The Outpatient Burden of Respiratory Syncytial Virus Infections in Older Children. 61
27738053 2017
49
Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico. 61
27439650 2017
50
Effect of climate on incidence of respiratory syncytial virus infections in a refugee camp in Kenya: A non-Gaussian time-series analysis. 61
28570627 2017

Variations for Respiratory Syncytial Virus Infectious Disease

Expression for Respiratory Syncytial Virus Infectious Disease

LifeMap Discovery
Genes differentially expressed in tissues of Respiratory Syncytial Virus Infectious Disease patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 6.10 0.000
2 OLFM4 olfactomedin 4 Blood + 5.54 0.000
3 PRTN3 proteinase 3 Blood + 5.47 0.000
4 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Blood + 5.04 0.000
5 MMP8 matrix metallopeptidase 8 Blood + 4.32 0.000
6 MPO myeloperoxidase Blood + 4.23 0.000
7 HP haptoglobin Blood + 4.21 0.000
8 CTSG cathepsin G Blood + 4.10 0.000
9 DEFA4 defensin, alpha 4, corticostatin Blood + 3.98 0.000
10 OTOF otoferlin Blood + 3.94 0.000
11 OLFM1 olfactomedin 1 Blood - 3.93 0.000
12 RETN resistin Blood + 3.90 0.000
13 ARG1 arginase 1 Blood + 3.89 0.000
14 GPR84 G protein-coupled receptor 84 Blood + 3.88 0.000
15 NOV nephroblastoma overexpressed Blood - 3.79 0.000
16 ELANE elastase, neutrophil expressed Blood + 3.76 0.000
17 RHAG Rh-associated glycoprotein Blood + 3.73 0.000
18 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Blood + 3.68 0.000
19 MAOA monoamine oxidase A Blood + 3.62 0.000
20 ZDHHC19 zinc finger, DHHC-type containing 19 Blood + 3.62 0.000
21 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 Blood + 3.55 0.000
22 KCNG1 potassium channel, voltage gated modifier subfamily G, member 1 Blood - 3.48 0.000
23 HBBP1 hemoglobin, beta pseudogene 1 Blood + 3.45 0.000
24 AZU1 azurocidin 1 Blood + 3.43 0.000
25 ANXA3 annexin A3 Blood + 3.42 0.000
26 COL17A1 collagen, type XVII, alpha 1 Blood + 3.39 0.000
27 CD177 CD177 molecule Blood + 3.38 0.000
28 PRSS33 protease, serine, 33 Blood - 3.36 0.000
29 METTL7B methyltransferase like 7B Blood + 3.33 0.000
30 GPR42 G protein-coupled receptor 42 (gene/pseudogene) Blood + 3.27 0.000
31 C1QC complement component 1, q subcomponent, C chain Blood + 3.24 0.000
32 KCTD14 potassium channel tetramerization domain containing 14 Blood + 3.22 0.000
33 DEFA3 defensin, alpha 3, neutrophil-specific Blood + 3.20 0.000
34 FGF9 fibroblast growth factor 9 Blood - 3.15 0.000
35 PTGDR2 prostaglandin D2 receptor 2 Blood - 3.15 0.000
36 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.13 0.000
37 ADGRE4P adhesion G protein-coupled receptor E4, pseudogene Blood - 3.11 0.000
38 MMP28 matrix metallopeptidase 28 Blood - 3.09 0.000
39 XK X-linked Kx blood group Blood + 3.08 0.000
40 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Blood + 3.04 0.000
41 KIF5C kinesin family member 5C Blood - 3.03 0.000
42 DLK1 delta-like 1 homolog (Drosophila) Blood + 3.01 0.000
43 LRRC26 leucine rich repeat containing 26 Blood - 3.01 0.000
44 LTF lactotransferrin Blood + 3.00 0.000
Search GEO for disease gene expression data for Respiratory Syncytial Virus Infectious Disease.

Pathways for Respiratory Syncytial Virus Infectious Disease

Pathways related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 NEU1 IRF1 IL5 IL13 IFNB1 CCL5
2
Show member pathways
13.15 IRF1 IL5 IL13 IFNB1 CCL5 CCL3
3
Show member pathways
12.74 IRF1 IL5 IL13 IFNB1 CCL5 CCL3
4
Show member pathways
12.17 IL5 IL13 IFNB1
5
Show member pathways
11.91 IRF1 IL5 IL13 IFNB1
6 11.7 IRF1 IFNB1 CCL5
7 11.66 IRF1 IFNB1 CCL3
8 11.46 IRF1 IL5 IL13
9 11.4 IL5 IL13 CCL3
10 11.25 IL5 IL13
11 11.14 IRF1 IFNB1
12 11.12 IL13 CCL5 CCL3
13 11.07 IL5 IL13
14 11 IRF1 IL13
15 10.96 IL5 IL13
16 10.92 IFNB1 CCL5
17 10.73 IL5 IL13 CCL5 CCL3
18 10.72 IL5 IL13 CCL5 CCL3
19 10.59 IL5 IL13 IFNB1
20 10.57 IL5 IL13

GO Terms for Respiratory Syncytial Virus Infectious Disease

Cellular components related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.43 SFTPB IL5 IL13 IFNB1 CCL5 CCL3
2 extracellular region GO:0005576 9.17 SFTPB NEU1 IL5 IL13 IFNB1 CCL5

Biological processes related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.72 IL5 CCL5 CCL3
2 immune response GO:0006955 9.67 IL5 IL13 CCL5 CCL3
3 positive regulation of smooth muscle cell proliferation GO:0048661 9.59 IL13 CCL5
4 positive chemotaxis GO:0050918 9.58 CCL5 CCL3
5 monocyte chemotaxis GO:0002548 9.58 CCL5 CCL3
6 negative regulation of viral genome replication GO:0045071 9.57 IFNB1 CCL5
7 positive regulation of B cell proliferation GO:0030890 9.56 IL5 IL13
8 protein kinase B signaling GO:0043491 9.54 CCL5 CCL3
9 lymphocyte chemotaxis GO:0048247 9.52 CCL5 CCL3
10 lipopolysaccharide-mediated signaling pathway GO:0031663 9.51 CCL5 CCL3
11 positive regulation of JAK-STAT cascade GO:0046427 9.49 IL5 CCL5
12 positive regulation of calcium ion transport GO:0051928 9.48 CCL5 CCL3
13 eosinophil chemotaxis GO:0048245 9.46 CCL5 CCL3
14 inflammatory response GO:0006954 9.46 IL5 IL13 CCL5 CCL3
15 positive regulation of innate immune response GO:0045089 9.43 IFNB1 CCL5
16 cellular response to interferon-beta GO:0035458 9.4 IRF1 IFNB1
17 macrophage chemotaxis GO:0048246 9.32 CCL5 CCL3
18 negative regulation by host of viral transcription GO:0043922 9.26 CCL5 CCL3
19 cytokine-mediated signaling pathway GO:0019221 9.02 IL5 IL13 IFNB1 CCL5 CCL3
20 positive regulation of natural killer cell chemotaxis GO:2000503 8.96 CCL5 CCL3

Molecular functions related to Respiratory Syncytial Virus Infectious Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL5 CCL3
2 chemoattractant activity GO:0042056 9.4 CCL5 CCL3
3 CCR chemokine receptor binding GO:0048020 9.37 CCL5 CCL3
4 cytokine receptor binding GO:0005126 9.32 IL13 IFNB1
5 CCR5 chemokine receptor binding GO:0031730 9.26 CCL5 CCL3
6 phospholipase activator activity GO:0016004 9.16 CCL5 CCL3
7 cytokine activity GO:0005125 9.02 IL5 IL13 IFNB1 CCL5 CCL3
8 CCR1 chemokine receptor binding GO:0031726 8.96 CCL5 CCL3

Sources for Respiratory Syncytial Virus Infectious Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....